MelanomaBox

Task 3.1 — Reasoning Trace

Nomination

Trametinib + Alpelisib + Capivasertib, each at 1/3 of its listed recommended concentration:

• Trametinib: 10 nM → 3.33 nM (MEK1/2 inhibitor)
• Alpelisib: 5 µM → 1.667 µM (PI3Kα inhibitor)
• Capivasertib: 5 µM → 1.667 µM (pan-AKT inhibitor)

Predicted % viability at 16 h (CTG): ~58%.

Key driver: LOXIMVI genetics

LOXIMVI is a human melanoma line that is BRAF wild-type and NRAS wild-type (no BRAF^V600 driver). This single fact reshapes the candidate list:

• BRAF inhibitors are the wrong tool here. Vemurafenib, Dabrafenib, and Encorafenib are selective for the BRAF^V600 mutant conformation. In BRAF-WT cells they give little MAPK suppression and can drive paradoxical activation of ERK signaling through RAF dimerization/CRAF transactivation. Including any of them risks raising viability rather than lowering it. They are excluded.
• This is the opposite situation from A375 (BRAF^V600E), where those same inhibitors would be top choices.

Pathway logic for a BRAF-WT melanoma

With no targetable BRAF allele, durable single-pathway MAPK shutdown is hard and melanoma cells readily escape via the parallel PI3K/AKT survival axis. The established high-value strategy is vertical co-inhibition of MAPK and PI3K/AKT:

1. Trametinib (MEK1/2) — acts downstream of BRAF, so it suppresses ERK signaling independent of BRAF mutation status. It is the most potent MEK inhibitor in the list (nanomolar; recommended 10 nM vs 30–100 nM for the others), so even after the 1/3 reduction (3.33 nM) it sits near its effective range. This is the strongest available MAPK-arm hit.
2. Alpelisib (PI3Kα) + Capivasertib (pan-AKT) — co-block the PI3K→AKT survival arm at two consecutive nodes. Hitting both the lipid kinase (PI3Kα) and the effector kinase (AKT) limits feedback reactivation that occurs when only one node is inhibited (e.g., loss of S6K→IRS negative feedback re-activates AKT under MEK inhibition). This buffers the dose reduction and blunts the adaptive PI3K rebound that MEK inhibition itself triggers.

Combining MEK + PI3K + AKT therefore attacks the two pathways LOXIMVI depends on for proliferation and survival, and does so with the most potent agents available for each arm.

Why this beats the alternatives

• Three MEK inhibitors (e.g., Trametinib + Cobimetinib + Binimetinib): redundant — all converge on the same node, so the second and third drugs add little beyond what trametinib already achieves, while leaving the PI3K/AKT escape route fully open.
• Any BRAF inhibitor–containing trio: ineffective-to-counterproductive in BRAF-WT cells (paradoxical ERK activation, see above).
• Regorafenib-based trios: regorafenib is a broad multikinase inhibitor (VEGFR/PDGFR/KIT/RET/RAF/FGFR) with largely angiogenesis/stroma-directed targets that are not the proliferative drivers of an isolated melanoma monolayer; its on-target anti-proliferative contribution here is less specific than vertical MAPK+PI3K/AKT blockade.
• TAK-733 or other MEK + PI3K/AKT: reasonable, but trametinib is the more potent, better-characterized MEK inhibitor, so it is the preferred MAPK-arm component.

Predicted viability rationale (~58%)

• Short 16 h endpoint: these are predominantly cytostatic targeted agents, not acute cytotoxins. Sixteen hours is too short for substantial apoptotic collapse; CTG (ATP) signal reflects mostly arrested-but-alive cells plus modest early death. Large viability drops (<30%) are not expected at this timepoint for any kinase-inhibitor trio.
• 1/3 dose reduction: each agent is below its listed concentration, further limiting the magnitude of effect.
• Net: combined MAPK + PI3K/AKT blockade should produce a meaningful but moderate reduction — estimated ~58% viability relative to DMSO control at 16 h, which I expect to be the lowest among chemically rational trios from this list given LOXIMVI's BRAF-WT background.

Caveat: this is a mechanism-based prediction with no experimental readout provided; actual CTG values depend on LOXIMVI's specific PI3K/PTEN status and assay dynamics.

Task 3.1 — Reasoning trace

Cell line context: LOX-IMVI

LOX-IMVI (Cellosaurus CVCL_1381, DepMap ACH-000750) is an amelanotic human melanoma line that is BRAF p.Val600Glu (V600E) heterozygous (ClinVar VCV000013961; confirmed in COSMIC, DepMap, CCLE). This is the canonical actionable MAPK driver and the basis for choosing therapy. The line is broadly reported as MAPK-pathway addicted and sensitive to BRAF/MEK inhibition (e.g., used as a reference V600E melanoma model in NCI-60 and DepMap PRISM screens).

Beyond the MAPK driver, LOX-IMVI carries co-alterations that keep the PI3K/AKT arm partially active (reported PTEN status varies across sources from intact to reduced/partial loss). In V600E melanoma generally, residual PI3K/AKT signalling is a well-described escape route from MAPK monotherapy and a rationale for a third hit on this arm.

Drug rationale at 1/3 of recommended dose

All candidates remain pharmacologically meaningful at 1/3 of listed doses.

Combination selection

Strategy: combine vertical MAPK blockade (BRAFi + MEKi) with a parallel PI3K/AKT arm inhibitor. This triple-node block is the most consistently synergistic regimen reported for BRAF V600E melanoma (preclinical and clinical, e.g., dabrafenib + trametinib + AKT/PI3K inhibitors in BRAFm tumours).

Picked combination: Dabrafenib (33 nM) + Trametinib (3.3 nM) + Capivasertib (1.67 µM).

Why this trio over alternatives:

1. Dabrafenib + Trametinib is the best-validated BRAFi+MEKi pairing (approved combination), with the cleanest evidence of pERK shutdown in V600E melanoma. Both are saturating or near-saturating at 1/3 dose, so the dose cut does not meaningfully erode MAPK suppression.
2. Capivasertib (pan-AKT) hits the downstream node of the PI3K/AKT survival axis directly, irrespective of which PI3K isoform feeds it. This is more robust than choosing Alpelisib (PI3Kα-selective only) given uncertainty in isoform usage in LOX-IMVI.
3. Why not BRAFi + 2 MEKi or 2 BRAFi: target redundancy — adding a second MEK inhibitor (e.g., TAK-733) on top of trametinib does not deepen pathway suppression since trametinib at 3.3 nM already saturates MEK.
4. Why not regorafenib: broad multi-kinase activity is less specifically synergistic; off-target tox at 16h would not show in this short ATP readout.
5. Why not encorafenib + binimetinib + capivasertib: a reasonable alternative — encorafenib's long target residence (~30 h) gives durable MAPK block, and binimetinib is the partner of record. Predicted viability would be similar. I chose dab + tram because both are more potent at 1/3 dose (deeper MAPK shutdown by 16 h matters more than residence at this short timepoint), and the literature on dabrafenib + trametinib + AKTi triplets in V600E melanoma is more developed.

Predicted viability at 16 h

CellTiter-Glo at 16 h measures intracellular ATP, which begins to drop when cells halt proliferation and engage apoptotic/bioenergetic stress programmes. BRAFi+MEKi typically produces strong G1 arrest in V600E lines within 6–12 h; early apoptosis markers (cleaved caspase) appear by 24 h. At 16 h with triple blockade including AKT inhibition (which suppresses survival signalling and accelerates apoptosis onset), the ATP signal should fall further than BRAFi+MEKi alone.

Empirical reports for dab+tram on V600E melanoma typically show 70–85% viability at 16–24 h (mostly cytostatic at this window). Adding an AKT inhibitor at near-IC50 concentration in a sensitive V600E line, based on the magnitude of synergy reported for MEKi+AKTi triplets, would push this down to roughly 60–70% viability at 16 h. I predict ~65%.

This is intentionally not an aggressive prediction — 16 h is too short to see the full cytotoxic effect of MAPK + PI3K/AKT triple blockade, which manifests as cell death over 24–72 h. Predictions much lower than ~55% at 16 h would not be biologically realistic for these compounds.

Confidence and limitations

• Mutation status (BRAF V600E het) is well established; PTEN/PI3K co-alteration details vary by source, which is part of why I picked the downstream AKT inhibitor over an isoform-selective PI3K inhibitor.
• No experimental dose-response data were available for this task; the viability estimate is a prior based on published BRAFi/MEKi/AKTi pharmacology in V600E melanoma, the chosen 1/3 doses, and the 16 h endpoint constraint.
• The combination assumes additive-to-synergistic effects with no antagonism; in V600E lines this is generally supported but specific synergy for LOX-IMVI + dab/tram/capivasertib has not been individually characterised in the literature I can confirm.

Task 3.1 — Reasoning trace

Nomination

Regorafenib (1.67 µM) + Trametinib (3.33 nM) + Capivasertib (1.67 µM) Predicted % viability at 16 h: ~62% (Each value = 1/3 of listed dose: Regorafenib 5 µM→1.67 µM; Trametinib 10 nM→3.33 nM; Capivasertib 5 µM→1.67 µM.)

Key constraint: LOXIMVI genetics

LOXIMVI is BRAF wild-type and NRAS wild-type — no BRAF V600E driver. Therefore the BRAF inhibitors (Vemurafenib, Dabrafenib, Encorafenib) are poor choices: they only work in BRAF V600E cells and can cause paradoxical ERK activation in a RAF/RAS-WT background. All three are excluded.

Key constraint: 16 h is a very short endpoint

CTG tracks viable cell number via ATP. At 16 h, purely cytostatic agents (e.g. MEK inhibitors alone) have not had time to translate arrest into viability loss (that matures over 48–72 h). The combination needs an acutely cytotoxic/pro-apoptotic component plus removal of parallel survival signals.

Why these three

1. Regorafenib (1.67 µM) — broad multi-kinase inhibitor with relatively fast low-micromolar cytotoxicity/apoptosis; carries the bulk of the early 16 h signal.
2. Trametinib (3.33 nM) — potent MEK1/2 inhibitor acting downstream of BRAF, so it suppresses MAPK/ERK survival signaling regardless of LOXIMVI's BRAF-WT status (the advantage MEK inhibitors hold over BRAF inhibitors here).
3. Capivasertib (1.67 µM) — pan-AKT inhibitor blocking the parallel PI3K/AKT/mTOR survival axis, converting MAPK-blockade cytostasis into apoptosis.

Trametinib + Capivasertib = classic dual vertical blockade of the two principal survival pathways (MAPK + PI3K/AKT), a well-established pro-apoptotic synergy; Regorafenib adds the broad acute cytotoxicity needed to register at 16 h.

Why this beats alternatives

• BRAF-inhibitor-containing combos: wasted slot / paradoxical MAPK activation in BRAF-WT LOXIMVI.
• Stacked MEK inhibitors: redundant target, purely cytostatic, minimal 16 h effect.
• Alpelisib + Capivasertib + X: PI3Kα and AKT are vertical in the same pathway (partly redundant) and leave MAPK uncovered; substituting Trametinib adds orthogonal MAPK coverage.
• Regorafenib + Alpelisib + Capivasertib: maximizes micromolar cytotoxic load but under-covers MAPK; the chosen trio's dual-axis design is mechanistically more complete.

Predicted viability rationale

At 16 h even a complete combination yields only a moderate drop (full targeted-agent cytotoxicity needs longer). Regorafenib's acute effect plus dual survival-pathway blockade → estimated ~62% viability vs DMSO control.

Task 3.1 Rationale

Nomination: Encorafenib + Trametinib + Capivasertib.

LOXIMVI is a melanoma model expected to be strongly dependent on mutant BRAF/MAPK signaling. At one third of the listed concentrations, encorafenib remains a potent RAF inhibitor and trametinib remains a potent MEK inhibitor, so the pair should deeply suppress MAPK output at the 16 hour endpoint. I selected capivasertib as the third agent because AKT inhibition adds non-overlapping blockade of PI3K/AKT survival signaling, a common resistance and persistence route in BRAF-driven melanoma, and should increase early loss of ATP signal versus adding another RAF or MEK inhibitor.

I did not prioritize alpelisib because PI3K-alpha selectivity is less broadly matched to melanoma survival signaling than downstream AKT inhibition, especially when PTEN/AKT activation may be relevant. I did not prioritize regorafenib because much of its anti-angiogenic target profile is not useful in a short in vitro CTG assay, and its RAF activity is less specific than a dedicated BRAF inhibitor. The predicted 32% viability reflects substantial but incomplete early killing/metabolic suppression at 16 hours, before the full multi-day cytotoxic effect would be expected.

Reasoning Trace: Task 3.1

Cell Line Genetics

LOXIMVI is a human melanoma cell line harboring a BRAF V600E mutation (documented in CCLE and NCI-60 datasets). This makes it highly sensitive to BRAF and MEK inhibitors, which are the cornerstone of targeted therapy in BRAF-mutant melanoma.

Candidate Drug Analysis

BRAF Inhibitors

• Vemurafenib (1/3 dose: 333 nM) — first-gen BRAF V600E inhibitor; effective but lower selectivity
• Dabrafenib (1/3 dose: 33 nM) — second-gen BRAF inhibitor; clinically paired with trametinib
• Encorafenib (1/3 dose: 33 nM) — third-gen BRAF inhibitor; highest potency and longest target residence time; clinically paired with binimetinib

MEK Inhibitors

• Trametinib (1/3 dose: 3.3 nM) — allosteric MEK1/2 inhibitor; paired with dabrafenib clinically
• Cobimetinib (1/3 dose: 33 nM) — MEK inhibitor paired with vemurafenib
• Binimetinib (1/3 dose: 33 nM) — MEK inhibitor paired with encorafenib (COLUMBUS trial); effective at nM concentrations
• TAK-733 (1/3 dose: 10 nM) — potent MEK inhibitor; preclinical

Other Pathway Inhibitors

• Regorafenib (1/3 dose: 1.67 µM) — multikinase inhibitor; broad but less selective for MAPK
• Alpelisib (1/3 dose: 1.67 µM) — PI3Kα inhibitor; targets bypass pathway
• Capivasertib (1/3 dose: 1.67 µM) — pan-AKT inhibitor (IC50 ~3–14 nM for AKT1/2/3); at 1.67 µM, robustly active

Rationale for Nominated Combination: Encorafenib + Binimetinib + Capivasertib

Why this triple?

1. Encorafenib + Binimetinib is a clinically validated, approved combination for BRAF V600E melanoma (COLUMBUS trial). Encorafenib's long target residence time and high potency, combined with binimetinib's MEK blockade, produces synergistic MAPK pathway suppression. At 33 nM each (1/3 of 100 nM), both remain within pharmacologically active ranges.

1. Capivasertib addresses the PI3K/AKT bypass pathway. In BRAF-mutant melanoma, MAPK pathway inhibition can cause feedback activation of PI3K/AKT signaling, reducing the efficacy of BRAF+MEK inhibition alone. Blocking AKT with capivasertib at 1.67 µM (well above its nM-range IC50) eliminates this escape mechanism and produces additive/synergistic cytotoxic stress.

1. Triple MAPK + AKT blockade maximally suppresses survival signaling in BRAF V600E LOXIMVI cells, expected to produce the greatest reduction in viability of any available 3-drug combination from the candidate list.

Why not other combinations?

• Using two BRAF inhibitors together offers no additive benefit (same target, competing binding).
• BRAF inhibitor + two MEK inhibitors: redundant MEK blockade unlikely to outperform BRAF+MEK+AKT.
• Alpelisib (PI3Kα) vs Capivasertib (pan-AKT): Capivasertib hits AKT1/2/3 directly downstream of PI3K, providing broader and more immediate suppression of AKT-driven survival signaling.

Timepoint Consideration (16 hrs)

At 16 hours, cells are undergoing early signaling disruption but have not yet undergone significant proliferation-based death. The viability reduction is primarily due to acute signaling stress and early apoptotic induction rather than full cell death. Therefore, even in the optimal combination, viability will not drop to very low values (like 10–20%), but will show meaningful reduction from ~100% DMSO control.

Predicted Viability

~60% — A meaningful reduction reflecting early MAPK + AKT pathway suppression in BRAF V600E-mutant LOXIMVI cells at 16 hours. This estimate accounts for:

• The 1/3 dose reduction (partial but still pharmacologically relevant concentrations)
• The early 16-hour timepoint (cells stressed but not yet fully killed)
• The synergistic combination of dual MAPK pathway blockade + AKT inhibition